Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Nov 2020
Randomized Controlled Trial Comparative StudyTicagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI). ⋯ In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding. Due to the post hoc nature of the analysis, these findings need confirmation by further studies. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800).